The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib
L Porcelli, E Giovannetti, YG Assaraf… - Current drug …, 2014 - ingentaconnect.com
… inhibitor Ko143 did not increase erlotinib sensitivity, but did … of BCRP expression, trafficking
and drug transport activity. These … of erlotinib with drugs that are BCRP transport substrates. …
and drug transport activity. These … of erlotinib with drugs that are BCRP transport substrates. …
Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib
YH Ling, T Li, R Perez-Soler, M Haigentz - Cancer chemotherapy and …, 2009 - Springer
… erlotinib and tunicamycin in human NSCLC cell lines which can be exploited in clinical studies
of novel drug combinations with erlotinib. … After blocking with 5% bovine serum albumin in …
of novel drug combinations with erlotinib. … After blocking with 5% bovine serum albumin in …
Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro
P Biegański, M Godel, C Riganti, DF Kawano… - Bioorganic …, 2022 - Elsevier
… erlotinib and other target therapy drugs the lung cancer treatment have improved a lot in recent
years. However, erlotinib-… of erlotinib together with their anticancer activity studies against …
years. However, erlotinib-… of erlotinib together with their anticancer activity studies against …
Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver
… Drug Administration (FDA) [Citation2]. ERL is available in oral tablet form under the trade
name Tarceva ® … As with most anticancer drugs, poor water solubility brings many drawbacks, …
name Tarceva ® … As with most anticancer drugs, poor water solubility brings many drawbacks, …
Dual stimuli-responsive release of aptamer AS1411 decorated erlotinib loaded chitosan nanoparticles for non-small-cell lung carcinoma therapy
K Saravanakumar, A Sathiyaseelan… - Carbohydrate …, 2020 - Elsevier
… The drug loading, and entrapment efficiency of erlotinib in CSNPs was determined at
absorbance of 346 nm using the high-performance liquid chromatography (HPLC). …
absorbance of 346 nm using the high-performance liquid chromatography (HPLC). …
Modulation of signaling enhances the efficacy of the combination of satraplatin and erlotinib
… After blocking the arrays with 2% bovine serum albumin (BSA) and subsequent loading of the
… Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma …
… Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma …
Pharmacokinetic properties of two erlotinib 150 mg formulations with a genetic effect evaluation in healthy Korean subjects
HG Choi, JY Jeon, YJ Im, Y Kim, EK Song… - Clinical drug …, 2015 - Springer
… [47], the data in this study are a valuable addition to the field of drug development. This
study suggests that the test and reference formulations of erlotinib 150 mg have similar …
study suggests that the test and reference formulations of erlotinib 150 mg have similar …
[HTML][HTML] … of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient …
RH Berndsen, A Weiss, UK Abdul, TJ Wong… - Scientific reports, 2017 - nature.com
… erlotinib/RAPTA-C combination by identifying effective drug dose ratios and studying the
mechanism of action of this drug … The membrane was blocked with 5% bovine serum albumin in …
mechanism of action of this drug … The membrane was blocked with 5% bovine serum albumin in …
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma
MD Prados, KR Lamborn, S Chang, E Burton… - Neuro …, 2006 - academic.oup.com
… Growth factors, erythropoietin, new CYP3A/4 inhibitors, and other investigational drugs were
not permitted nor was previous use of erlotinib. All patients signed an informed consent form…
not permitted nor was previous use of erlotinib. All patients signed an informed consent form…
The role of Self-Nanoemulsifying drug delivery systems of CDODA-Me in sensitizing Erlotinib-Resistant non–small cell lung cancer
… treatment involving ERL (erlotinib) with a glycyrrhetinic acid … using self-nanoemulsifying
drug delivery systems (SNEDDS). … to optimize drug content, particle size, and drug release. …
drug delivery systems (SNEDDS). … to optimize drug content, particle size, and drug release. …